Triple Negative Breast Cancer - An Overview

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Triple Negative Breast Cancer (TNBC) is defined by negative estrogen receptor (ER), progesterone receptor (PR), and HER2 expression via immunohistochemistry (IHC).
• TNBC disproportionately affects young African American and Hispanic women, frequently associated with BRCA1 gene mutations.
• This cancer subtype exhibits aggressive behavior and a lack of specific targeted therapies, posing significant clinical challenges.

Purpose of the Study:

• To review current and emerging novel signaling pathways for therapeutic strategies against TNBC.
• To highlight the potential of a recently discovered BRCA1 trafficking pathway for future targeted therapy development.

Main Methods:

• Literature review of current research on TNBC signaling pathways.
• Analysis of recent findings on BRCA1 gene function and cellular trafficking.
• Exploration of potential therapeutic targets based on identified pathways.

Main Results:

• TNBC is a heterogeneous disease with a distinct molecular profile and aggressive clinical course.
• BRCA1 gene mutations are prevalent in certain demographics affected by TNBC.
• A novel BRCA1 trafficking pathway has been recently identified.

Conclusions:

• The identified BRCA1 trafficking pathway presents a promising avenue for developing targeted therapies for TNBC.
• Further research into this pathway could lead to novel treatment strategies for patients with TNBC, particularly those with BRCA1 mutations.